Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 23, 2012, under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,300,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,415.5 pence per share; lowest price paid was 1,401 pence per share.
- Treasury Holdings (Settled): 509,690,427 shares (9.36% of total issued share capital).
- Treasury Holdings (Including Unsettled): 513,190,427 shares (10.40% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,935,577,065 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,300,000 shares. This transaction increased the proportion of shares held in Treasury from the prior settled position to 10.40% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (509,690,427 settled vs. 513,190,427 including unsettled).
- Confirm the impact of the 10.40% Treasury holding on total voting rights calculations.
- Check the remaining authorization for share repurchases under the May 3, 2012 shareholder mandate.
- Review the Financial Services Authority's Disclosure and Transparency Rules regarding notification thresholds for shareholders.